trending Market Intelligence /marketintelligence/en/news-insights/trending/75q3cikf25kuiz3yp8kjiw2 content
Log in to other products

Login to Market Intelligence Platform

 /

Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Intec Pharma appoints director

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Intec Pharma appoints director

Intec Pharma Ltd. appointed Roger Pomerantz as a director.

Pomerantz's appointment brings the number of Intec's board members to seven, six of whom are independent. Pomerantz is the president, CEO and board chairman of Seres Therapeutics Inc.

Jerusalem, Israel-based Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Accordion Pill is an oral drug delivery system designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.